Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2013 2
2014 2
2015 3
2016 1
2017 6
2018 3
2019 7
2020 4
2021 9
2022 8
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. Lancet JE, et al. Among authors: bixby dl. J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19. J Clin Oncol. 2018. PMID: 30024784 Free PMC article. Clinical Trial.
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. Lancet JE, et al. Among authors: bixby dl. Lancet Haematol. 2021 Jul;8(7):e481-e491. doi: 10.1016/S2352-3026(21)00134-4. Lancet Haematol. 2021. PMID: 34171279 Clinical Trial.
Pure erythroid leukemia.
Chen JC, Lee WY, Schaefer JK, Bixby DL. Chen JC, et al. Among authors: bixby dl. Clin Case Rep. 2020 Sep 18;8(11):2286-2288. doi: 10.1002/ccr3.3056. eCollection 2020 Nov. Clin Case Rep. 2020. PMID: 33235778 Free PMC article.
Oncology stewardship in acute myeloid leukemia.
Ochs MA, Marini BL, Perissinotti AJ, Foucar CE, Pettit K, Burke P, Bixby DL, Benitez LL. Ochs MA, et al. Among authors: bixby dl. Ann Hematol. 2022 Aug;101(8):1627-1644. doi: 10.1007/s00277-022-04872-1. Epub 2022 May 26. Ann Hematol. 2022. PMID: 35618780 Review.
Catalyzing improvements in ALL therapy with asparaginase.
Marini BL, Perissinotti AJ, Bixby DL, Brown J, Burke PW. Marini BL, et al. Among authors: bixby dl. Blood Rev. 2017 Sep;31(5):328-338. doi: 10.1016/j.blre.2017.06.002. Epub 2017 Jul 5. Blood Rev. 2017. PMID: 28697948 Review.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Numan Y, et al. Among authors: bixby dl. Am J Hematol. 2022 Mar 1;97(3):322-328. doi: 10.1002/ajh.26447. Epub 2022 Jan 7. Am J Hematol. 2022. PMID: 34981560 Free article. Clinical Trial.
46 results